GALIMEDIX THERAPEUTICS, INC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://www.galimedix.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-101, 2%, ophthalmic solution in patients with non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration: eDREAM study
Phase 2
Recruiting
- Conditions
- Non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Galimedix Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- 2024-519128-26-00
- Locations
- 🇮🇪
Institute Of Eye Surgery Limited, Waterford, Ireland
News
No news found